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Summary
Endocannabinoids are released after brain injury and
believed to attenuate neuronal damage by binding to
CB1 receptors and protecting against excitotoxicity.
Suchexcitotoxicbrain lesions initially result inprimary
destruction of brain parenchyma, which attracts mac-
rophages and microglia. These inflammatory cells re-
lease toxiccytokinesand free radicals, resulting insec-
ondary neuronal damage. In this study, we show that
theendocannabinoid system ishighly activatedduring
CNS inflammation and that theendocannabinoid anan-
damide (AEA) protects neurons from inflammatory
damage by CB1/2 receptor-mediated rapid induction
of mitogen-activated protein kinase phosphatase-1
(MKP-1) in microglial cells associated with histone H3
phoshorylation of the mkp-1 gene sequence. As a re-
sult, AEA-induced rapid MKP-1 expression switches
off MAPK signal transduction in microglial cells acti-
vated by stimulation of pattern recognition receptors.
The release of AEA in injured CNS tissue might there-
fore represent a new mechanism of neuro-immune
communication during CNS injury, which controls and
limits immune response after primary CNS damage.
*Correspondence: oliver.ullrich@medizin.uni-magdeburg.de
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The endocannabinoid system, consisting of cannabi-
noid receptors, their endogenous ligands, and enzymes
for synthesis and degradation of endocannabinoids, is
known to play a crucial role in neuronal signal transduc-
tion. Cannabinoid-sensitive sites inside the brain in-
clude the neuronal CB1 cannabinoid receptor (Matsuda
et al., 1988) and its counterpart in the immune system,
the CB2 receptor (Munro et al., 1993). The endogenous
ligands, the endocannabinoids, are made through cleav-
age of membrane precursors and are involved in various
signaling processes. Whereas the metabolic pathways
of anandamide (AEA), a small lipid molecule sharing
structural features with the eicosanoids, are unique and
release of the compound in the living brain occurs on de-
mand (Di Marzo et al., 1994; Giuffrida et al., 1999; Walker
et al., 1999), 2-arachidonoylglycerol (2-AG) has been de-
tected in much higher concentrations in brain tissue
than anandamide, is formed in central intersections of
lipid metabolism, and is therefore suggested to be en-
gaged in housekeeping functions, additionally to its sig-
naling functions (Sugiura et al., 1995; Mechoulam et al.,
1995; Piomelli and Greengard, 1990, Piomelli, 2003).
During neuronal activity, the endogenous cannabinoid
AEA is formed by glutamate receptor agonists in a Ca2+-
dependent manner or by stimulation of dopamine D2 re-
ceptors in a G-protein-coupled process (Giuffrida et al.,
1999). In the neuronal network, endocannabinoids medi-
ate a localized signaling mechanism through which prin-
cipal neurons modify the strength of incoming synaptic
inputs (Alger, 2002; Wilson and Nicoll, 2002): in the
CA1 field of the hippocampus, membrane depolariza-
tion opens voltage-activated Ca2+ channels in pyramidal
neurons and therefore stimulates the synthesis of 2-AG
and AEA. The endocannabinoids then travel backward
across the synapse to interact with CB1 receptors on
axon terminals of GABAergic interneurons, leading to
depolarization-induced suppression of inhibition (DSI).
Such retrograde signaling by endocannabinoid-medi-
ated DSI occurs in the hippocampus but has also been
shown outside the hippocampus at interneuron-princi-
pal cell synapses (Llano et al., 1991; Kreitzer and Regehr,
2001; Trettel and Levine, 2003).
Interestingly, endogenous cannabinoids are also re-
leased after brain injury (Panikashvili et al., 2001; Hansen
et al., 2001; Marsicano et al., 2003; Mechoulam and
Lichtman, 2003; Franklin et al., 2003) and are believed
to attenuate neuronal damage by binding to CB1 recep-
tors (Panikashvili et al., 2001; Hansen et al., 2001; Marsi-
cano et al., 2003) and protecting against excitotoxicity
(Marsicano et al., 2003; Mechoulam and Lichtman, 2003).
Such excitotoxic brain lesions initially result in primary
destruction of brain parenchyma, which attracts macro-
phages and microglia, the major effector cells within the
CNS. These inflammatory cells produce large amounts
of toxic cytokines and oxygen radicals that subsequently
result in secondary neuronal damage. Although it is
known that the cannabinoid receptors CB1 and CB2 are
expressed on microglial cells (Carrier et al., 2004;
Neuron
68Facchinetti et al., 2003; Waksman et al., 1999) and that
activated microglia are capable of producing larger
amounts of endogenous cannabinoids than neurons
(Walter et al., 2003), the function of the endocannabi-
noid system within the CNS immune system has not
been elucidated. In this study, we reveal a function of
the endocannabinoid system not related to neurons
but affecting nerve cell function and survival after brain
injury. We show that the endocannabinoid system is
highly activated during CNS inflammation and protects
neurons from inflammatory damage by inducing a novel
intracellular negative feedback loop in microglial cells
acting via CB1/2-mediated epigenetic regulation of
MKP-1 expression.
Results
The Endocannabinoid System Is Activated
during CNS Inflammation and Protects Neurons
from Inflammatory Damage
To investigate whether the endocannabinoid system is
activated during inflammation within the brain paren-
chyma, we first analyzed endocannabinoid concentra-
tions in CNS tissue from inflammatory lesions of patients
with active or silent multiple sclerosis (MS) and normal
control patients by gas chromatography/mass spec-
trometry (GC/MS) (Witting et al., 2004a). In inflammatory
lesions of patients with active MS, we found a 3.7-fold
higher concentration of the endocannabinoid ananda-
mide (AEA) and a 1.9-fold higher concentration in lesions
of patients with silent MS, in comparison to healthy con-
trols (Figure 1A). Levels of other endocannabinoids, such
as 2-arachidonoylglycerol (2-AG) and palmitoylethano-
lamide (PEA), were only slightly influenced (data not
shown). Because damage to neuronal structures has
only recently been suggested to be a key mechanism
during the development of MS (Trapp et al., 1998; Hem-
mer et al., 2002), we next addressed the question of
whether the accumulation of AEA might be a direct con-
sequence of neuronal damage or because of invading
immune cells. Thus, we used an approach that allows
the study of the effects of immunoeffector cell invasion
into living organotypic brain tissue, the organotypic hip-
pocampal slice culture system (OHSC) (Heppner et al.,
1998; Ullrich et al., 2001; Diestel et al., 2003). In this
model, exogenously cultivated microglia migrate into
OSHCs toward the site of neuronal injury (Heppner
et al., 1998), where they induce inflammatory conditions
and associated tissue reactions (Heppner et al., 1998;
Ullrich et al., 2001; Diestel et al., 2003). In living brain
tissue, we detected a 2.8-fold increase in AEA concen-
tration after induction of specific excitotoxic neuronal
damage by N-methyl-D-aspartate (NMDA) that was po-
tentiated up to a 13.2-fold increase after invasion of
BV-2 microglial cells (Figure 1B). BV-2 microglial cells
exhibit morphologic and functional features comparable
to primary microglial cells (Diestel et al., 2003; Bocchini
et al., 1992) and did not induce AEA production in a rest-
ing state (Figure 1B).
Because AEA accumulated in inflamed brain tissue,
the question arises about its influence on inflammatory
damage to neurons. To address this, we transferred BV-2
microglial cells onto excitotoxically damaged OHSCs
from mice and quantified the damage in the neuronalcell layers (pyramidal cell layer of the cornu ammonis
and granule cell layer of the dentate gyrus) after 3 days
(Ullrich et al., 2001; Adamchik et al., 2000; Laake et al.,
1999). As demonstrated in Figure 1C, incubation with
NMDA resulted in primary neuronal damage that was po-
tentiated by the invasion of microglial cells, resulting in
severe secondary damage. Incubation with 2 mM AEA
completely abolished inflammatory damage but not the
primary excitotoxic damage (Figure 1C). Incubation with
AEA alone did not increase neuronal damage (Figure 1C).
In order to investigate whether this AEA-mediated pro-
tection occurred as a consequence of other mechanisms
of neuronal cell damage, we subjected OHSCs to oxygen
glucose deprivation (OGD) and assessed neuronal sur-
vival after 3 days of microglial invasion, as described
above. Here, incubation with 2mM AEA reduced neuronal
damage to the level of OGD-induced primary damage
(Figure 1D). Because we observed no direct protection
of neurons by AEA, neither in the NMDA nor in the OGD
model in OHSCs, we investigated the protection of pri-
mary neurons subjected to NMDA- or OGD-induced
injury in isolated primary neurons by measurement of
LDH activity (Figure 1E): 2 mM AEA was not capable of
protecting primary neurons directly against NMDA,
which was also the case after OGD (319.2 6 36.5 U/ml
LDH release 24 hr after OGD versus 359.2 6 22.3 U/ml
LDH release 24 hr after OGD + AEA). These data indicate
that the endocannabinoid AEA protects neurons from
inflammatory damage very efficiently, but not from direct
injury resulting from excitotoxicity or oxygen-glucose
deprivation.
In order to investigate a possible protective role of the
endogenous cannabinoid system during the develop-
ment of inflammatory neuronal damage, we transferred
BV-2 microglial cells onto the surface of NMDA-dam-
aged OHSCs in the presence of 0.5mM AM 251, a specific
CB1 receptor antagonist, and 2 mM AM 630, a specific
CB2 receptor antagonist, and assessed damage in the
neuronal layers of the hippocampus after 3 days. In this
experiment, cannabinoids were not added to the brain
tissue, and only the activity of endogenously formed
cannabinoids was addressed. To allow the detection of
a possible further enhancement of inflammatory neuro-
nal damage after cannabinoid receptor inhibition, we re-
duced the time of primary NMDA-damage (2 hr instead of
4 hr compared to Figure 1C), resulting in lower primary
and secondary inflammatory neuronal damage (2.4-fold
and 4.1-fold, respectively, Figure 2) as baseline. CB2 re-
ceptor inhibition elevated the extent of inflammatory
damage by 40% (from 4.1-fold to 5.8-fold), whereas CB1
receptor inhibition had no effect (Figure 2). In conclusion,
the endocannabinoid system protects neurons from in-
flammatorydamage inaCB2 receptor-dependentmanner.
Activity on Cannabinoid Receptors Suppresses
Inflammatory Attack in Healthy Brain Tissue
Interestingly, without primary neuronal damage, BV-2
microglial cells release only small amounts of nitric ox-
ide (2.28 6 0.14 mM without neuronal damage versus
15.626 2.66 mM after neuronal damage) and affect neu-
ronal viability only slightly (Figure 2). This means that
microglial cells, although present in large amounts in-
side the living OHSC tissue, are obviously under strict
control in a healthy brain enviroment. In contrast, after
Microglia-Mediated Neuroprotection by Anandamide
69Figure 1. The Endocannabinoid System Is Activated during CNS Inflammation and Protects Neurons from Inflammatory Damage
(A) Accumulation of AEA in inflammatory lesions of patients with multiple sclerosis. Absolute anandamide (AEA) concentrations detected by GC/
MS10 are demonstrated for control patients and patients with chronic silent or active MS lesions. Data are given as mean 6 S.D. con, control
patients (n = 7); silent MS (n = 6); and active MS (n = 5); asterisk, p < 0.05 (active MS versus silent MS and controls, silent MS versus controls).
(B) Accumulation of AEA in living brain tissue after invasion of microglial cells. Concentration of anadamide (AEA) in the living brain tissue of hip-
pocampal slice cultures (OHSCs) after initial specific neuronal damage induced by 5 mM NMDA with or without transfer of 105 BV-2 microglial
cells (BV-2), in comparison to untreated controls (con). Data are given as mean 6 S.D., n = 3 for each group. Asterisk, p < 0.05 (BV-2 after
NMDA damage versus NMDA damage without BV-2 and BV-2 without NMDA damage, NMDA damage versus BV-2 without NMDA damage).
(C) Top: pictures of propidium iodide fluorescence microscopy of the regions of neuronal injury in the cornu ammonis and dentate gyrus in living
organotypic brain slice cultures after NMDA damage. Con, no treatment; AEA, incubation with 2 mM AEA; NMDA, induction of primary neuronal
damage with 5 mM NMDA for 4 hr; BV-2, 3 days after transfer of 105 BV-2 microglial cells. One representative picture of each group is shown.
(C) Bottom: propidium iodide fluorescence in the neuronal cell layers after NMDA damage. Results are given as propidium iodide fluorescence in
the neuronal layers after treatment relative to nondamaged brain tissue. Control, no treatment; AEA, incubation with 2 mM AEA; NMDA, induction
of primary neuronal damage with 5 mM NMDA for 4 hr; BV-2, 3 days after transfer of 105 BV-2 microglial cells. Data are given as mean 6 S.D.
(n = 6); asterisk, p < 0.05 (BV-2 + AEA versus BV-2 and BV-2 versus AEA or con in the NMDA treated group, NMDA damage versus AEA, BV-2
+ AEA, BV-2 and con in the nondamaged group, BV-2 versus con in the nondamaged group).
(D) Propidium iodide fluorescence in the neuronal cell layers after oxygen glucose deprivation. Results are given as propidium iodide fluores-
cence in the neuronal layers after treatment relative to nondamaged brain tissue. con, no treatment; AEA, incubation with 2 mM AEA; OGD, ox-
ygen glucose deprivation, BV-2, 3 days after transfer of 105 BV-2 microglial cells. Data are given as mean6 S.D. (n = 6); asterisk, p < 0.05 (BV-2 +
AEA versus BV-2).
(E) No direct protection of neurons by AEA from excitotoxic damage. Release of LDH activity after incubation with 5 mM NMDA with or without
2 mM AEA is demonstrated. Data are given as mean 6 S.D. (n = 3).cannabinoid receptor inhibition, neuronal damage exac-
erbates to 3.6-fold after CB1 receptor inhibition and to
3.8-fold after CB2 receptor inhibition (Figure 2). Thus,
activity on CB1 and CB2 cannabinoid receptors sup-
presses microglial cell attack on healthy brain tissue
and therefore prevents the CNS from endogenous in-
flammatory damage as a potential nondesired side
effect of continuous immune surveillance. Conversely,
downregulation of the endocannabinoid system might
therefore result in a loss of control and an ongoing at-
tack of microglial cells on neurons.
CB1/2-Dependent ERK-1/2 Dephosphorylation
and Suppression of Nitric Oxide Synthesis
in Activated Microglial Cells
In the next set of experiments, we examined the path-
way that prevents invading immunoeffector cells frominitiating severe inflammatory damage. For this, we in-
vestigated the release of proinflammatory cytokines in
cultured BV-2 microglial cells and of the cytotoxic free
radical nitric oxide (NO) after stimulation with lipopoly-
saccharide (LPS), which acts via CD14/TLR4. In these
experiments, we revealed a distinct dose-dependent re-
duction of NO release by AEA (Figure 3A, left), and also
by the CB1/2 agonist WIN 55,212-2 (Figure 3A, right),
associated with suppression of inducible nitric oxide
synthetase (iNOS) (Figure 3C). Moreover, release of the
proinflammatory cytokine IL-6 was delayed (381 6 47
pg/ml with 2 mM AEA versus 1095 6 254 pg/ml without
AEA after 12 hr) but reached similar levels after 24 hr.
In contrast, release of TNF-a was not impaired (data
not shown). Excessive production of NO has been pos-
tulated to elicit immune-mediated neurodegenerative
inflammatory processes and to cause brain injury
Neuron
70(Mabuchi et al., 2000; Stoll et al., 1998). To clarify
whether the abrogated NO release was due to specific
interaction between AEA and CB1/2 receptors, we incu-
bated OHSCs infiltrated with microglia with the pharma-
cological antagonists AM251 to CB1 and AM630 to CB2
receptors. In these experiments, we showed that the
abolished NO release at least partially returns after in-
cubation with both antagonists and that CB2 blockade
was more effective than CB1 blockade (Figure 3B). This
was also supported by experiments with blocking anti-
bodies against CB1 and CB2 receptors, which restored
the NO release to 21.2 6 0.9 mg/ml (anti-CB1) or 7.21 6
0.34 mg/ml (anti-CB2), respectively. Therefore, we con-
clude that AEA is capable of suppressing NO release
in microglial cells inside inflamed brain tissue via inter-
actions with CB1/2 receptors.
Next, we addressed the question of which signaling
pathway might be responsible for suppressed microglia
activation by LPS/AEA coincubation. Incubation with
Figure 2. Endogenous Cannabinoid Receptor Activation Protects
Neurons in Damaged and Healthy Brain Tissue
Top: pictures of propidium iodide fluorescence microscopy of the
regions of neuronal injury in the cornu ammonis and dentate gyrus
in healthy living organotypic brain slice cultures or after NMDA dam-
age. Control, no treatment; NMDA, induction of primary neuronal
damage with 5 mM NMDA for 2 hr; BV-2, 3 days after transfer of
105 BV-2 microglial cells; AM 251, incubation with 0.5 mM of the
CB1 receptor antagonist AM 251; AM 630, incubation with 2 mM of
the CB2 receptor antagonist AM 630. One representative picture of
each group is shown. Bottom: propidium iodide fluorescence in
the neuronal cell layers in healthy OHSC tissue or after NMDA dam-
age. Results are given as propidium iodide fluorescence in the neu-
ronal layers after treatment relative to nondamaged brain tissue, leg-
end as in top panel. Data are given as mean 6 S.D. (n = 6); asterisk,
p < 0.05 (BV-2 + AM 630 versus BV-2 and with BV-2 versus without
BV-2 in the NMDA damaged group, BV-2 + AM 630 versus BV-2 and
BV-2 + AM 251 versus BV-2 in the nondamaged group) with 0.5 mM of
the CB1 receptor antagonist AM 251; AM 630, incubation with 2 mM
of the CB2 receptor antagonist AM 630. One representative picture
of each group is shown.AEA alone caused Thr202/Thr204 phosphorylation of ex-
tracellular signal-regulated kinase-1/2 (ERK-1/2) after
8 hr (Figure 4A) as a consequence of activation of the
mitogen-activated protein kinase (MAPK) pathway, as
reported previously (Derkinderen et al., 2003). LPS alone
induced ERK-1/2 phosphorylation after 2 hr (Figure 4A).
Surprisingly, in the presence of both stimuli (1 hr preincu-
bation with AEA or WIN 55,212-2 followed by LPS stimu-
lation), phosphorylation of ERK-1/2 was not potentiated
or even sustained but was reduced (Figure 4B). In this
case, as a result of 1 hr preincubation with AEA (Derkin-
deren et al., 2003), the initial ERK-1/2 phosphorylation
disappeared completely after LPS stimulation. There-
fore, we assume that anandamide sets microglial cells
into a state of alert by rapid MAPK-phosphorylation,
but prevents (over-)activation in the presence of a sec-
ond stimulus. The phosphorylation state of ERK-1/2 is
generally regulated by the balance of upstream kinases
or phosphatases. But in contrast to the rapid phosphor-
ylation of ERK kinase (MEK) in microglial cells after LPS
treatment alone (Figure 4C), LPS treatment after preincu-
bation and in the presence of AEA or WIN 55,212-2 re-
duced and delayed MEK phosphorylation (Figure 4C).
Because the constant or enhanced MEK activation after
LPS treatment in the presence of AEA or WIN 55,212-2
(Figure 4C) did not account for ERK-1/2 dephosphoryla-
tion (Figure 4B), we next focused on the regulation of
ERK-1/2-dephosphorylating phosphatases by AEA.
Anadamide Induced MKP-1, which Colocalized
with Invading Microglial Cells in Inflammatory
Lesions of Patients with Multiple Sclerosis
In these experiments, a rapid induction of mitogen-
activated protein kinase-phosphatases-1 and -2 (MKP-1
and MKP-2) occurred within 1 hr of treatment WIN
55,212-2 and within 2 hr of treatment with AEA com-
bined with LPS (Figure 5B): induction of MKP-1 and
MKP-2 protein expression occurred early after the onset
of cannabinoid receptor stimulation. Here, we observed
maximal induction of MKP-1 and MKP-2 after 2 hr AEA
treatment, whereas LPS resulted in MKP-1 induction af-
ter 12 hr and MKP-2 induction after 4 hr (Figure 5A). This
time course indicated that MKP-1 and MKP-2 induc-
tion was a direct effect of CB1/2 stimulation rather than
an indirect effect triggered by initial MAPK activation
(Shapiro and Ahn, 1998). Moreover, incubation with
Ro-318220, an inhibitior of MKP expression (Guo et al.,
1998), prevented ERK-1/2 dephosphorylation in cul-
tured microglial cells costimulated with AEA/LPS (Figure
5C). These findings suggest a pivotal role of MKP-1 and
MKP-2 in the regulation and control of inflammatory re-
actions within the CNS. Thus, we investigated whether
invading microglial cells in inflammatory lesions in the
CNS actually expressed MKP-1 and MKP-2 and ana-
lyzed brain tissue from patients with MS by double-
fluorescence microscopy (Figure 6A). As shown in rep-
resentative pictures in Figure 6A, we found expression
of MKP-1 in cells of inflammatory brain lesions colocal-
ized with Ox42-positive microglia in the presence of high
AEA concentrations (Figure 1A) but much lower expres-
sion and lack of colocalization of MKP-2 with microglial
cells. Thus, we conclude that MKP-1 is indeed ex-
pressed in microglia cells during CNS inflammation (Fig-
ure 6A) induced by high levels of the endocannabinoid
Microglia-Mediated Neuroprotection by Anandamide
71Figure 3. CB1/2-Dependent Suppression of Nitric Oxide Synthesis and Nitric Oxide Synthetase Induction in Activated Microglial Cells
(A) CB1/2 stimulation by AEA or WIN 55,212-2 abrogates nitric oxide release. BV-2 microglial cells were incubated with 2, 5, 10 mM AEA (left) or 2, 5,
10 mM WIN 55,212-2 for 1 hr before activation by LPS. Data are given as mean6S.D. (n = 6); asterisk, p < 0.05 at 24 hr (2, 5, or 10 mM AEA or 2, 5, 10
mM WIN versus con without treatment).
(B) Reduction of NO release in microglia-invaded living brain tissue by AEA is CB1/2 dependent. NMDA-damaged organotypic hippocampal brain
slice cultures were incubated with 2 mM AEA after transfer of 105 BV-2 microglial cells in the presence of 0.5 mM of the CB1 receptor antagonist AM
251 or 2 mM of the CB2 receptor antagonist AM 630. Data are given as mean6 S.D. (n = 3). Asterisk, p < 0.05 at 24 hr (BV-2 + AEA versus BV-2 +
AEA + AM 251 or BV-2 + AEA+ AM 630 or BV-2 without treatment).
(C) Reduction of iNOS expression by AEA in activated microglia. BV-2 microglial cells were activated by LPS with (bottom) or without (top) co-
incubation with 2 mM AEA. Data are given as signal intensity relative to 0 min (mean6S.D., n = 3). Asterisk, p < 0.05 (time points versus 0 min). One
representative immunoblot is demonstrated.AEA (Figure 1A). Because formation of inflammatory
lesions (Figure 6A) depends strongly on cell migration
and because cannabinoid-receptor stimulation increase
microglia cell migration in vitro (Walter et al., 2003), we
next tested whether CB1- or CB2-receptor activity is re-
quired for migration of microglial cells into the regions of
neuronal injury in living brain slice cultures. We found
that site-specific microglia migration is strongly dis-
turbed in the presence of the CB1- and CB2-receptor an-
tagonists AM251 and AM630, respectively (Figure 6B).
Differential Regulation of MAPK Signal Transduction
by AEA Depends on the Presence of a Second Signal
Signals of LPS or AEA alone are transduced via the
MAPK pathway and resulted in an elevated and sus-
tained ERK-1/2 phosphorylation (Figure 4C). Moreover,
LPS stimulation induced ERK-1/2 phosphorylation
more rapidly (after 2 hr) than AEA stimulation (after 8
hr). Sustained ERK-1/2 phosphorylation was associated
with slowly increasing MKP-1 induction after 12 hr
(Figure 5A), which might represent a negative feedback
loop of MAPK activation as described earlier (Shapiro
and Ahn, 1998). But in contrast, in the presence of
both LPS and AEA, MKP-1 was induced rapidly and sig-
nificantly after 2 hr, reached expression levels higher
than after LPS or AEA stimulation alone, and remained
constantly elevated (Figure 5B). As a consequence,stimulation with LPS was not capable of inducing
ERK-1/2 phosphorylation in the presence of AEA but be-
came almost completely dephosphorylated after 24 hr
(Figure 4B). Initial ERK-1/2 phosphorylation as shown
in Figure 4B results from 1 hr preincubation with AEA
alone before stimulation with LPS.
In order to verify our assumption that MKP-1 induction
is not a secondary consequence of MAPK pathway acti-
vation (Shapiro and Ahn, 1998), we incubated LPS-stim-
ulated microglial cells with the MEK inhibitor U0126 and
found no difference in MKP-1 expression after 12 hr
treatment in the presence of AEA but a complete abro-
gation of MKP-1 expression after treatment with LPS
alone (Figure 7A). Moreover, in the presence of CB1 or
CB2 antagonists, AEA failed to induce MKP-1 expres-
sion (Figure 7B). Therefore, we conclude that AEA-in-
duced MKP-1 expression is a primary, CB1/2-mediated
effect and not secondary to MAPK activation. To inves-
tigate whether the neuroprotective effect of AEA is me-
diated by MAPK activation or by CB1/2 stimulation or
both, we then assessed cell damage in the neuronal
layers of OHSCs invaded by microglial cells as de-
scribed above (Figure 7C). In these experiments, we
found that MAPK-pathway inhibition by U0126 did not
influence neuroprotection, whereas it was attenuated
by CB1 inhibition and completely abrogated by CB2 inhi-
bition (Figure 7C). Taken together, AEA alone activates
Neuron
72Figure 4. CB1/2-Dependent ERK-1/2 Phosphorylation in Resting Microglial Cells and ERK-1/2 Dephosphorylation in Activated Microglial Cells
(A) ERK-1/2 phosphorylation in stimulated microglial cells in the presence of AEA. ERK-1/2 is phosphorylated after incubation with AEA or LPS.
BV-2 microglial cells were incubated with 10 mg/ml LPS (top) or with 2 mM AEA (bottom). Data are given as signal intensity of p-ERK-1 and p-ERK-
2 relative to 0 min (mean 6 S.D., n = 3). Asterisk, p < 0.05 (time points versus 0 min). One representative immunoblot is demonstrated.
(B) ERK-1/2 dephosphorylation in LPS-activated microglial cells in the presence of AEA or WIN-55,212,-2. ERK-1/2 is dephosphorylated in LPS-
activated BV-2 microglial cells after incubation with 2 mM AEA (top) or 2 mM WIN 55,212-2, a CB1/2-receptor agonist (bottom). Data are given as
signal intensity of p-ERK-1 and p-ERK-2 relative to 0 min (mean 6 S.D., n = 3). Asterisk, p < 0.05 (time points versus 0 min). One representative
immunoblot is demonstrated.
(C) Reduction of MEK-phosphorylation in LPS-activated microglial cells in the presence of AEA or WIN-55,212-2. MEK phosphorylation is re-
duced in LPS-activated BV-2 microglial cells after incubation with 2mM AEA (top) or 2 mM WIN 55,212-2, a CB1/2-receptor agonist (bottom).
Data are given as signal intensity of p-MEK relative to 0 min (mean6 S.D., n = 3). Asterisk, p < 0.05 (time points versus 0 min). One representative
immunoblot is demonstrated.MAPK pathway, but switches off MAPK signal transduc-
tion by rapid MKP-1 induction in the presence of a sec-
ond stimuli on microglial pattern recognition receptors.
Anandamide Induced Rapid Phosphorylation
of Histone H3 on the mkp-1 Gene and MKP-1
Expression in Microglial Cells, which Suppresses
Nitric Oxide Release and Inflammatory Damage
in Living Brain Tissue
To investigate whether blocking of NO release by AEA
was the result of MKP-1 induction, we transferred BV-
2 microglial cells—either transfected with MKP-1 siRNA
or control siRNA to OHSCs—and followed the release of
NO during the inflammatory process over the course of 3
days (Figure 7D). Here, microglial cells with silenced
MKP-1 responded very weakly to AEA incubation com-
pared to the controls, suggesting that the reduced NO
release in the presence of AEA (Figure 3A) was indeed
MKP-1 dependent (Figure 5B). As a consequence of
the functional role of microglial MKP-1 during endocan-nabinoid-mediated cell-to-cell communication during
CNS inflammation, we focused on the regulation of
mkp-1 gene expression. Whereas little is known about
the transcriptional regulation of mkp-1, direct and fast
regulation of mkp-1 by phosphorylation of histone H3
has been previously reported (Li et al., 2001). Thus, we
performed chromatin-immunoprecipitation experiments
with an anti-phospho-histone H3 antibody and analyzed
mkp-1 expression in the precipitated underlying DNA
sequences. We found that costimulation with LPS and
AEA, but not with LPS or AEA alone, resulted in en-
hanced histone H3 phosphorylation of the mkp-1 gene
sequence (Figure 7E). Thus, the rapid MKP-1 protein
expression after LPS/AEA costimulation might be ex-
plained by histone modification and provides for the first
time a link between cannabinoid-mediated signal trans-
duction and regulation of ‘‘histone code’’ (Jenuwein and
Allis, 2001).
Finally, we investigated whether CB1/2 receptors or
MKP-1 expression in BV-2 microglial cells (Figure 8A)
Microglia-Mediated Neuroprotection by Anandamide
73Figure 5. Expression of MKP-1 in Inflammatory Microglial Cells
(A) Induction of MKP-1 and MKP-2 expression in microglial cells in the presence of LPS or AEA. MKP-1 and MKP-2 expression is induced after
incubation with AEA or LPS. BV-2 microglial cells were incubated with 10 mg/ml LPS (top) or with 2 mM AEA (bottom). Data are given as signal
intensity of MKP-1 and MKP-2 relative to 0 min (mean6 S.D., n = 3). Asterisk, p < 0.05 (time points versus 0 min). One representative immunoblot
is demonstrated.
(B) Induction of MKP-1 and MKP-2 expression in LPS-activated microglial cells in the presence of AEA or WIN-55,212,-2. MKP-1 and MKP-2
expression is induced rapidly in LPS-activated BV-2 microglial cells after incubation with 2 mM AEA (top) or 2 mM WIN 55,212-2, a CB1/2-receptor
agonist (bottom). Data are given as signal intensity of MKP-1 and MKP-2 relative to 0 min (mean 6 S.D., n = 3). Asterisk, p < 0.05 (time points
versus 0 min). One representative immunoblot is demonstrated.
(C) MKP expression inhibition abrogates dephosphorylation of ERK-1/2 by AEA in LPS-stimulated BV-2 microglia. BV-2 microglial cells were
activated by 10 mg/ml LPS and 2 mM AEA with or without 10 mM Ro-318220, a MKP–expression inhibitor. Data are given as signal intensity of
p-ERK-1 and p-ERK-2 relative to 0 min (mean6 S.D., n = 3). Asterisk, p < 0.05 (time points versus 0 min). One representative immunoblot is dem-
onstrated.and primary microglial cells (Figure 8B) were functionally
involved in AEA-mediated neuroprotection in living brain
tissue. As demonstrated in Figures 8A and 8B, CB1 inhi-
bition attenuated and CB2 inhibition abrogated neuro-
protection by AEA in inflamed brain tissue. Moreover,
inhibitor experiments with Ro-318220 as well as siRNA-
silencing experiments confirmed that MKP-1 expression
is also required for AEA-induced neuroprotection by BV-
2 microglial cells (Figure 8A) as well as primary microglial
cells (Figure 8B). In conclusion, AEA induced neuropro-
tection by CB1/2-receptor stimulation and induction of
MKP-1 expression in microglial cells of inflammatory
brain lesions.
Discussion
Beside neurons, cells of the innate immune system are
also capable of producing endocannabinoids (Walter
and Stella, 2004), such as macrophages (Liu et al.,2003; Kuwae et al., 1999; Di Marzo et al., 1999) and mi-
croglial cells (Witting et al., 2004b), after stimulation.
For instance, the binding of ATP to purinergic P2X7 re-
ceptors rapidly induces a Ca2+-dependent release of en-
docannabinoids (Witting et al., 2004b), resulting in ele-
vated concentrations in brain and spinal cord (Piomelli,
2003). Thus, endocannabinoids might represent a com-
mon messenger used by both the nervous and immune
systems. In the mammalian brain, the CB1 receptor is
present in the neocortex, hippocampus, basal ganglia,
cerebellum, and brainstem, where it is primarily found
on glutamatergic and axon terminals of GABA interneur-
ons and accounts for most of the behavioral actions of
cannabinoid drugs (Chaperon and Thiebot, 1999; Her-
kenham et al., 1990). Because of its property as a Gi/o-
coupled receptor, CB1 can initiate signaling events typ-
ical of this class of transducing proteins, such as closure
of Ca2+ channels, opening of K+ channels, and inhibition
of adenylyl cyclase activity, resulting in a decrease in
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ceptor Function in Tissue-Invading Microglial
Cells
(A) Colocalization of MKP-1, but not MKP-2,
with invading micoglial cells in inflammatory
lesions of patients with multiple sclerosis.
The colocalization of Ox42-positive micro-
glial cells (green) and MKP-1-oder MKP-2-
expressing cells (red) in inflammatory lesions
of patients with MS is demonstrated (yellow
in merger). The insert shows a representative
picture of an MKP-1-expressing microglial
cell in the inflammatory lesion.
(B) Migration of BV-2-microglial cells into the
neuronal layers of living brain tissue. Site-
specific migration of BV-2 microglial cells
into the neuronal cell layers of NMDA dam-
aged living organotypic brain slice cultures
(OHSC). Results are given as fluorescence
of Mini-Ruby-labeled (MR+) BV-2 microglial
cells in the neuronal layers after treatment rel-
ative to nondamaged brain tissue. Con, no
treatment; AEA, incubation with 2 mM AEA;
NMDA, induction of primary neuronal dam-
age with 5 mM NMDA for 4 hr; AM251, 0.5 mM of the CB1 receptor antagonist AM 251; AM 630, 2 mM of the CB2 receptor antagonist AM 630.
Data are given as mean 6 S.D. (n = 6); asterisk = p < 0.05 (NMDA versus NMDA + AM251 or NMDA + AM630, NMDA + AM251 versus NMDA +
AM630).cytosolic cAMP (Howlett, 1984). Subsequently, regula-
tion of neuronal gene expression by CB1 depends on
the recruitment of complex networks of intracellular
protein kinases such as extracellular signal-regulatedkinase (ERK) and focal adhesion kinase (FAK), which
become activated when hippocampal brain tissue is
treated with cannabinoid agonists (Derkinderen et al.,
1996, 2003). In this context, cannabinoid receptors areFigure 7. MKP-1 Expression and Neuropro-
tection after AEA Treatment Depends on
CB1/2 Activity, but Not on MAPK Activation,
Is Associated by Rapid Phosphorylation of
Histone H3 on the mkp-1 Gene, and Sup-
presses Nitric Oxide Release in Living Brain
Tissue
(A) AEA-induced MKP-1-expression is inde-
pendent from MAPK activation. BV-2 micro-
glial cells were stimulated for 12 hr with 10
mg/ml LPS with (+AEA) or without (2AEA) 2
mM AEA in the presence of 10 mM U0126, an
inhibitor of MEK1/2. One representative im-
munoblot is demonstrated.
(B) AEA-induced MKP-1 expression depends
on CB1- and CB2-receptor stimulation. BV-2
microglial cells were stimulated for 12 hr with
10 mg/ml LPS and 2 mM AEA in the presence
of 0.5 mM AM 251 or 2 mM AM 630 or on the
absence of CB1/2-receptor antagonists (con).
One representative immunoblot is demon-
strated.
(C) Propidium iodide fluorescence in the neu-
ronal cell layers in NMDA-damaged OHSCs.
Results are given as propidium iodide fluo-
rescence in the neuronal layers after treat-
ment relative to nondamaged brain tissue
(con). Primary neuronal damage was induced with 5 mM NMDA for 4 hr before transfer of 105 BV-2 microglial cells (all other groups). AEA, 2
mM AEA; U0126, 10 mM of the MEK1/2-inhibitor U0126; AM251, 0.5 mM of the CB1 receptor antagonist AM 251; AM 630, 2 mM of the CB2 receptor
antagonist AM 630; w/o, without inhibitors. Data are given as mean6 S.D. (n = 3); asterisk, p < 0.05 (AEA versus AEA + AM 630 and AEA + AM 251,
AEA + AM 251 versus AEA + AM 630, AEA versus w/o).
(D) Reduction of NO release by AEA is MKP-1 dependent. Control-siRNA-transfected or MKP-1-siRNA-transfected BV-2 microglial cells were
incubated with or without anandamide (AEA) before LPS stimulation. Data are given as mean 6 S.D. (n = 3). Asterisk, p < 0.05 (MKP-1-siRNA-
BV2 versus con-si-RNA-BV-2). The insert demonstrates downregulation of MKP-1 expression in AEA-treated BV-2 microglial cells by MKP-1
siRNA, which was 92.4% 6 5.6% compared to con siRNA.
(E) Enhanced association of phospho-histone H3 with mkp-1 gene sequence in LPS/AEA-treated BV-2 microglia cells. PCR of mkp-1 coding
sequence is demonstrated in chromatin immunoprecipitation (ChIP) with monoclonal anti-phospho-histone H3-antibody or in input controls be-
fore chromatin immunoprecipitation. The precipitation controls (without antibody) were blank (not shown).
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75Figure 8. Neuroprotection by AEA Depends on CB1/2 Receptors and Microglial MKP-1 Expression
(A) Propidium iodide fluorescence microscopy of the regions of neuronal injury in the cornu ammonis and dentate gyrus in living organotypic
brain slice cultures after NMDA damage and invasion of BV-2 microglial cells. One representative picture is demonstrated in the top panel. Con-
trol, no treatment; AEA, incubation with 2mM AEA; NMDA, induction of primary neuronal damage with 5 mM NMDA for 4 hr, BV-2, 3 days after
transfer of 105 BV-2 microglial cells; AEA, 2 mM AEA; AM251, 0.5 mM of the CB1 receptor antagonist AM 251; AM 630, 2 mM of the CB2 receptor
antagonist AM 630; Ro-318220, 10 mM Ro-318220; MKP-1-siRNA-BV-2, 3 days after transfer of 105 BV-2 microglial cells transfected with MKP-1-
siRNA; con-siRNA-BV-2, 3 days after transfer of 105 BV-2 microglial cells transfected with control-siRNA. Bottom: results are given as propidium
iodide fluorescence in the neuronal layers after treatment relative to nondamaged brain tissue. Data are given as mean 6 S.D. (n = 3); asterisk,
p < 0.05 (BV-2 + AM251, BV-2 + AM630, BV-2 + Ro-318220 versus BV-2, BV-2 versus BV-2 + AEA, con versus BV-2, MKP-1-siRNA-BV-2 versus
con-siRNA-BV-2).
(B) Pictures of propidium iodide fluorescence microscopy of the regions of neuronal injury in the cornu ammonis and dentate gyrus in living or-
ganotypic brain slice cultures after NMDA damage and invasion of primary microglial cells. One representative picture is demonstrated in the top
panel. Control, no treatment; AEA, incubation with 2 mM AEA; NMDA, induction of primary neuronal damage with 5 mM NMDA for 4 hr; MG, 3 days
after transfer of 105 primary microglial cells; AEA, 2 mM AEA; AM251, 0.5 mM of the CB1 receptor antagonist AM 251; AM 630, 2 mM of the CB2
receptor antagonist AM 630; Ro-318220, 10 mM Ro-318220; MKP-1-siRNA-MG, 3 days after transfer of 105 primary microglial cells transfected
with MKP-1-siRNA; con-siRNA-MG, 3 days after transfer of 105 primary microglial cells transfected with control-siRNA. Bottom: results are given
as propidium iodide fluorescence in the neuronal layers after treatment relative to nondamaged brain tissue. Data are given as mean 6 S.D.
(n = 3); asterisk, p < 0.05 (MG + AM251, MG + AM630, MG + Ro-318220 versus MG, MG versus MG + AEA, con versus MG, MKP-1-siRNA-MG
versus con-siRNA-MG).coupled to the activation of ERK (Wartmann et al., 1995;
Bouaboula et al., 1995a, 1995b, 1996) of c-junN-terminal
kinase and p38 mitogen-activated protein kinase (Liu
et al., 2000; Rueda et al., 2000). Moreover, the CB1 re-
ceptor is also coupled to the activation of protein kinase
B (PKB) (Gomez del Pulgar et al., 2000). Taken together,
in neuronal cells, cannabinoids inhibit the release of glu-
tamate and other neurotransmitters by blunting mem-
brane depolarisation and exocytosis (Schlicker and
Kathmann, 2001).
Most of the effects of cannabinoids are mediated by
their specific receptors, CB1 and CB2, which are coupled
to adenyl cyclase (AC) through heterotrimeric Gi/o pro-
teins (Galve-Roperh et al., 2000; Guzman et al., 2001).
However, in contrast to the CB1 receptor, transduction
systems responsible for CB2 receptor signaling are less
elucidated. CB2 receptors are expressed mainly by cells
of the immune system such as T cells, B cells, NK cells,
monocytes, microglial cells, and neutrophil granulocytes
(Galiegue et al., 1995). In these cells, inhibition of cAMP/protein kinase A (PKA) pathway may be responsible for
the immunosuppressive action of cannabinoids by de-
creasing the expression of cAMP-responsive genes
(Jacobsson et al., 2000). Moreover, CB2 receptor might
control immune-cell proliferation by coupling to ERK
activation, independent of cAMP (Sarker et al., 2000). In
our study, we demonstrated that cannabinoid-receptor
stimulation is coupled to ERK activation via regulation
of MKP-1 expression by histone H3 phosphorylation. In
cells of the immune system, CB2-receptor stimulation re-
sults in inhibitory signals (Walter and Stella, 2004), medi-
ated by inhibition of cAMP/PKA pathway and inhibition
of the transcription factors NF-AT und AP-1. We found
that inhibitory signal transduction in microglial cells de-
pends on parallel stimulation of pattern recognition re-
ceptors CD14/TLR4 by LPS. Endocannabinoids inhibit
CB2-mediated release of TNF-a, IL-1b, IL-6, and IL-8 by
monocytes/macrophages (Klegeris et al., 2003; Berdy-
shev et al., 1997; Gallily et al., 2002), which we could con-
firm at least for IL-6 in microglial cells. Our findings
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glial cells to the site of tissue damage by chemotaxis
(Franklin et al., 2003; Franklin and Stella, 2003; Walter
et al., 2003), where they help to control and limit local
immune response in order to prevent harmful over-
activation.
Here, we have found that the endocannabinoid AEA
induced histone H3 phosphorylation, MKP-1 expres-
sion, and subsequent ERK-1/2 dephosphorylation in ac-
tivated, but not in resting microglial cells, which in turn
abolishes NO release and finally results in neuroprotec-
tion. Our data indicative for increased anandamide lev-
els in MS lesions and previous studies reporting that
synthetic CB1/2-receptor agonists were capable of im-
proving neurological outcome in a murine model of en-
cephalomyelitis (Arevalo-Martin et al., 2003) are in line
with our experimental findings about the protective
role of endocannabinoid signaling in neuroinflammation.
The clinical use of cannabinoids or cannabinoid recep-
tor drugs for neuroprotective interventions during CNS
inflammation (Jackson et al., 2005; Klein, 2005) and for
treatment of MS are currently under discussion (Pryce
and Baker, 2005; Thompson and Baker, 2002; Killestein
et al., 2002). In our study, we conclude that release of the
endocannabinoid AEA in injured brain tissue might act
as a gatekeeper for signal transduction through the
MAPK pathway and represent an important negative
feedback loop within the CNS immune system needed
to reduce the extent of the inflammatory response and
to limit neurodegenerative immune reactions after pri-
mary brain damage. Moreover, endocannabinoid signal-
ing strongly suppresses attack of microglial cells on
nondamaged neurons, suggesting also a physiological
function of the endocannabinoid system in maintaining
a protective and healthy CNS microenviroment.
In conclusion, the endocannabinoid system repre-
sents a local messenger system between the nervous
and immune system and is obviously involved in the
control of immune activation and neuroprotection.
Therefore, elucidating the pathology of the endocanna-
binoid system during neuroinflammation and neurode-
generation might open new avenues of therapeutic in-
terventions in the future.
Experimental Procedures
Cell Cultures
BV-2 murine microglial cells, which exhibit morphologic and func-
tional properties comparable to primary microglial cells (Ullrich
et al., 2001; Bocchini et al., 1992), were cultured in DMEM medium
supplemented with 10% FCS at a density not exceeding 2 3 105
cells/ml. Microglial activation was performed by incubation with 10
mg/ml LPS (Sigma, St. Louis, MO) in the presence or absence of 2
mM, 5 mM, or 10 mM anandamide (Sigma) or 2 mM, 5 mM, or 10 mM
WIN 55,212-2 (Sigma). Labeling of microglial cells was performed
by incubation with culture medium containing 20 mg/ml Mini-Ruby
(MR), a 10 kDa dextran amine, conjugated with rhodamine (Molecu-
lar Probes, Eugene, OR). Primary microglia cells were prepared from
newborn mice with a modification (Ullrich et al., 2001) of the tech-
nique described by Giulian and Baker (Giulian and Baker, 1986). The
obtained primary microglia cell cultures were >95% pure. In vitro ex-
periments revealed no toxic effects of the inhibitors and substances
used (AEA, Ro-218200, U0126, AM221, AM630) on cultures of BV-2
microglial cells or primary microglial cells up to 3 days in the concen-
trations used in this study.
Primary neuronal cultures of cerebral cortex were obtained from
embryos (E16-E18) of Wistar rats (Bundesinstitut fu¨r gesundheitli-chen Verbraucherschutz und Veterina¨rmedizin, Berlin, Germany).
Cultures were prepared according to Brewer (1995). Excitotoxic
damage was induced by 5 mM NMDA for 4 hr. For oxygen glucose
deprivation (OGD), medium was removed from the cultures and pre-
served, and cells were rinsed twice with PBS and then subjected to
OGD for 60 min in a balanced salt solution at pO2 < 2 mm Hg, fol-
lowed by replacement of the preserved medium as described previ-
ously (Bruer et al., 1997). Neuronal injury was quantitatively as-
sessed by measurement of LDH activity in the medium after
NMDA or OGD exposure.
Investigations of Human Brain Tissue
Fresh frozen blocks of autopsied brain tissue from patients with
chronic active MS (n = 5), chronic silent MS (n = 6), and control pa-
tients (n = 7) were provided by two of us (C.S.R. and C.M.) on dry
ice (mean age/postmortem delay: 38 years/6.4 6 2.1 hr for patients
with chronic active MS, 49 years/3.5 6 0.9 hr for patients with
chronic silent MS and 56 years/7.6 6 1.3 hr for control patients).
CNS tissue from chronic active cases contained established, gliotic
lesions with evidence of recent inflammatory activity at the lesion
margins, and some fresh, acute MS lesions with edema, actively de-
myelinating margins rich in inflammatory cells and numerous hyper-
trophic astrocytes. Chronic silent cases displayed lesions that were
intensely gliotic and demyelinated with little evidence of inflamma-
tion. The 16 brain samples were assigned numbers and studied by
investigators blinded to the code.
Analysis of endocannabinoids were performed by GC/MS (Witting
et al., 2004a). 10 mm thick sections were briefly air dried and then im-
mersed in ice-cold acetone for 10 min. After incubation with blocking
buffer, sections were incubated with primary antibodies against
Ox42 (Abcam, Cambrigdeshire, UK, 1:200 dilution) and MKP-1 or
MKP-2 primary antibodies (Santa Cruz, CA, 1:200 dilution) for 1 hr
at room temperature. Slides were then incubated with secondary
antibodies conjugated to Cy2 (Jackson Laboratories, 1:50, for
Ox42 detection) or RedX (Jackson Laboratories, 1:50, for MKP-1
or MKP-2 detection). The sections were mounted in DPX (Fluka,
Neu-Ulm, Germany) and examined with a Leica TCS-NT laser scan-
ning confocal microscope (Heidelberg, Germany).
Preparation of Organotypic Hippocampal Slice Cultures
and Analysis of Inflammatory Neuronal Cell Death
OHSCs were obtained by decapitating newborn mice on the ninth to
tenth postnatal day, aseptically removing a frontal slice of the caudal
cerebrum and transversally sectioning it at a 350 mm thickness on
a sliding vibratome in MEM supplemented with 1% L-glutamine as
described earlier (Bocchini et al., 1992). OHSCs were cultured in cul-
ture medium (MEM:HBSS 2:1, 25% normal horse serum, 2% L-glu-
tamine, 2.64 mg/ml glucose and penicillin/streptomycin) at 35ºC
and 5% CO2 for 10 days in vitro to ensure a healthy organotypic mi-
croenvironment in the middle layer of the OHSCs, which is known to
induce microglial ramification (Ullrich et al., 2001; Diestel et al., 2003;
Bocchini et al., 1992). OHSCs were exposed to 5 mM NMDA for 4 hr,
after which the medium was exchanged.
BV-2 microglial cells (105 cells/OHSC) were transferred onto the
surface of OHSCs that had been cultured for 10 days. With this ap-
proach, the proportion of endogenous primary microglial cells is less
than 5% of the total microglial cell count (Ullrich et al., 2001). 3 days
after transferring the microglial cells, cell death at the sites of neuro-
nal injury (neuronal cell layers of cornu ammonis, CA, and dentate
gyrus, DG) was detected according to Adamchik et al. (Adamchik
et al., 2000) by the addition of 5 mg/ml propidium iodide (PI) to fresh
medium and incubation for 15 min. Dead cells within the neuronal
cell layers was quantified by fluorescence microscopy with a BX-
50 microscope (Olympus, Tokyo, Japan). Propidium-iodide fluores-
cence was selectively quantified in stratum granulare of the dentate
gyrus and stratum pyramidale of the cornu ammonis (identified by
bright field microscopy) by computer-assisted quantitative ap-
proach. Within these layers, almost exclusively neurons are located
(granule cells in the dentate and pyramidal cells in the cornu ammo-
nis). Fluorescence intensities obtained in the neuronal cell layers
only were corrected by the overall fluorescence measured through-
out the slice. Additional cell counts gave the same quantitative re-
sults. Correlation between fluorescence intensity and total numbers
of dead cells inside the hippocampal neuronal layers was linear
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77between 1 3 104 and 2 3 105 cells and not linear (saturation) above
23 105 cells. The low limit of quantification was 43 103 cells; differ-
ences of 53 103 dead cells resulted in significant changes in fluores-
cence intensity. Numbers of dead neuronal cells within the non-
treated control slice tissues were between 13 104 and 23 104 cells.
CB1 receptors were inhibited by 0.5 mM of AM 251 (N-[Piperidin-
1-yl]-5-[4-iodophenyl]-1-[2,4-dichlorophenyl]-4-methyl-1H-pyrazole-
3-carboxamide, Tocris), CB2 receptors were inhibited by 2 mM AM
630 (6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-me-
thoxyphenyl)methanone, Tocris), MKP-1-expression was inhibited
by 10 mM Ro-318220 (2-{1-[3-(Amidinothio)propyl]-1H-indol-3-yl}-
3-(1-methylindol-3-yl)maleimide Methanesulfonate, Sigma Aldrich,
Deisenhofen, Germany), and MAPK-activation by 10 mM U0126 (1,4-
diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene, Cell Sig-
naling, Beverly, MA).
Cell-Culture Experiments
Cells were lysed by repeated freeze-thawing cycles, and lysates
were used for experiments. Proteins were separated by 12% SDS/
PAGE, transblotted onto nitrocellulose membranes. The mem-
branes were incubated with antibodies directed against phospo-
ERK-1/2, ERK-1/2, phosphor-MEK, MEK (Cell Signaling, Beverly,
MA) and iNOS (Sigma, St. Louis, MO). After incubation with an ap-
propriate peroxidase-conjugated secondary antibody, the blots
were developed with a chemoluminescence (ECL) detection kit
(Amersham, Buckinghamshire, UK). Densitometric analysis was per-
formed by MetaMorph software, version 3.6a (Universal Imaging
Corp, West Chester, PA), relative to the 0 min signal and background
normalization. Statistical analysis was performed by the Wilcoxon
test (p < 0.05). Cannabinoid receptor antibodies for functional block-
ing were obtained from Biomol (Hamburg, Germany). The release of
nitric oxide was determined in a nitroblue tetrazolium assay and the
release of IL-6 and TNF-a by ELISA (Pharmingen, San Diego, CA).
SiRNA transfection against MKP-1 was performed according to
the protocol of Santa Cruz (Santa Cruz, CA) with transfection me-
dium, transfection reagent, MKP-1-siRNA (sc-35938), and control
siRNA (sc-35938) from Santa Cruz. Reduction of MKP-1 protein lev-
els after siRNA transfection have been quantified densitometrically
in Western blot anaysis and was 89.5%6 8.2%. Chromatin immuno-
precipitation was performed with a kit from Upstate (Waltham, MA)
according to the manufacturer’s recommendation with a mouse
monoclonal phospho-histone H3 antibody (Sigma, St. Louis, MO).
PCR analyses were performed with the following primer pairs: 50-
TCAGCGGGGAGTTTTTGTG-30 and 50-CTGTGAGTGACCCTCAAAG
TGG-30 for mkp-1 and 50-AACACCCCAGCCATGTACG-30 and 50-AT
GTCACGCACGATTTCCC-30 for b-actin according to Li et al. (Li
et al., 2001).
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